Evidence method
Level · gp.fundamentals.capex_revenue_ratio
0.70% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
RGNX · Jun 30, 2026
REGENXBIO Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001193125-26-336725General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-57.62% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
405.73% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.operating_margin
27.09% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
51.92% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
8.38% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History10 statesHistory building
Mar 31, 20240/6 normalizedLevel 3Jun 30, 20240/6 normalizedLevel 3Sep 30, 20240/6 normalizedLevel 3Dec 31, 20240/6 normalizedLevel 3Mar 31, 20250/6 normalizedLevel 3Jun 30, 20250/6 normalizedLevel 3Sep 30, 20250/6 normalizedLevel 3Dec 31, 20250/6 normalizedLevel 3Mar 31, 20265/6 normalizedLevel 3Jun 30, 20265/6 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 19.32%
- Current
- 0.70%
- Delta
- -18.61%
- Previous
- -1191.71%
- Current
- -57.62%
- Delta
- 1134.09%
- Previous
- -92.82%
- Current
- 405.73%
- Delta
- 498.55%
- Previous
- -1303.96%
- Current
- 27.09%
- Delta
- 1331.05%
- Previous
- 896.90%
- Current
- 51.92%
- Delta
- -844.98%
- Previous
- 134.79%
- Current
- 8.38%
- Delta
- -126.41%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Compared To · Biological Products, (No Diagnostic Substances) peers →Has State · REGENXBIO Inc. →Transitioned To · RGNX GROWTH_INCREASED →Transitioned To · RGNX PROFITABILITY_INCREASED →Transitioned To · RGNX R_AND_D_INTENSITY_DECREASED →Transitioned To · RGNX SBC_INTENSITY_DECREASED →Transitioned To · RGNX Fundamental State →Transitioned To · RGNX CAPEX_INTENSITY_DECREASED →Transitioned To · RGNX CASH_GENERATION_INCREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.